Marshall Wace, LLP Delcath Systems, Inc. Transaction History
Marshall Wace, LLP
- $90.8 Billion
- Q3 2025
A detailed history of Marshall Wace, LLP transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 288,763 shares of DCTH stock, worth $2.58 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
288,763
Previous 483,259
40.25%
Holding current value
$2.58 Million
Previous $6.57 Million
52.77%
% of portfolio
0.0%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding DCTH
# of Institutions
130Shares Held
13.1MCall Options Held
133KPut Options Held
159K-
Vanguard Group Inc Valley Forge, PA1.66MShares$14.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA688KShares$6.14 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT666KShares$5.95 Million0.29% of portfolio
-
State Street Corp Boston, MA621KShares$5.55 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA570KShares$5.09 Million0.97% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $76.8M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...